- RecruitingPHASE3
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
This study is looking at a new drug, casdatifan, combined with an existing one, cabozantinib, for advanced clear cell kidney cancer. It compares this combination to cabozantinib with a dummy drug (placebo) to see if it stops cancer growth for longer in patients who've already had immunotherapy.
For: Metastatic Clear Cell Renal Cell Carcinoma · Advanced Clear Cell Renal Cell CarcinomaUnited States · Australia · Canada - RecruitingPHASE1, PHASE2
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
This study is looking at an experimental drug called Pumitamig, by itself or with other treatments, for people with advanced kidney cancer (renal cell carcinoma). Researchers want to see how safe and effective these treatments are.
For: Advanced Renal Cell Carcinoma (RCC)United States · Argentina · Australia - RecruitingPHASE2
Pan Tumor Rollover Study
This study looks at the long-term safety of different cancer treatments, including nivolumab, alone or combined with other medicines. It's for people with various types of cancer who are already receiving treatment in a related study, aiming to see how these treatments work over time.
For: CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
This study is looking at new ways to treat advanced kidney cancer that hasn't been treated before. It combines three medicines to see if they work better together than two, aiming to help people live longer and keep their cancer from growing.
For: Renal Cell CarcinomaUnited States · Argentina · Australia - Active not recruitingPHASE3
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy
This study looks at new drug combinations for advanced liver cancer that hasn't been treated before. It compares cabozantinib with atezolizumab against a standard treatment, sorafenib, to see which works better and is safer.
For: Hepatocellular CarcinomaUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
This study compares a new drug, cabozantinib, with a dummy drug (placebo) for differentiated thyroid cancer that has continued to grow despite previous treatments. It aims to see if cabozantinib can slow down the cancer's progression.
For: Differentiated Thyroid CancerUnited States · Argentina · Australia - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
An open-label phase 1/2 study to evaluate the safety, biological response and efficacy of a single dose of Temferon (autologous CD34+-enriched hematopoietic stem and progenitors cells genetically modified with human Interferon-α2) in patients with metastatic renal cell carcinoma
This study is testing a new treatment called Temferon for advanced kidney cancer that has spread. It checks if Temferon is safe, how the body reacts to it, and how well it works in people who have already tried standard treatments.
For: Patients with locally advanced/metastatic renal cell carcinoma with evidence of disease progression following standard of care treatmentItaly - Active not recruitingPHASE1
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
This study is testing two anti-cancer drugs, cabozantinib and atezolizumab, alone and together, for various advanced cancers. It aims to find a safe combination dose and see how well it works and any side effects.
For: Urothelial Carcinoma · Renal Cell Carcinoma · Non-Small Cell Lung CancerUnited States · Australia · Belgium - Active not recruitingPHASE3
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
This study compares two treatments for advanced kidney cancer: a combination of belzutifan and lenvatinib, versus cabozantinib. It's for people whose cancer has grown even after previous treatment, aiming to find which option works better and is safer.
For: Carcinoma, Renal CellUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
This study is testing a new drug called selpercatinib for a type of thyroid cancer that has spread or can't be removed by surgery. It wants to see if this new drug is safer and works better than current treatments for people with a specific gene change (RET mutation).
For: Medullary Thyroid CancerUnited States · Australia · Belgium - Active not recruitingPHASE3
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
This study looks at a new combination of drugs, cabozantinib and atezolizumab, for men with prostate cancer that has spread and is no longer responding to hormone therapy. It compares this new combination with standard hormone treatments to see if it works better.
For: Metastatic Prostate Cancer · Prostate AdenocarcinomaUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
This study is testing new combinations of medicines (Nivolumab with Cabozantinib) against a standard treatment (Sunitinib) for kidney cancer that has spread. We want to see if the new combination is safer and works better for people who haven't had treatment before.
For: Renal Cell CarcinomaUnited States · Argentina · Australia